My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merus N.V. - Common Shares (NQ:MRUS)

94.15 +0.48 (+0.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merus N.V. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
MGM Resorts, Madison Square Garden Entertainment, Cardiovascular Systems And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
CORRECTING and REPLACING --Merus Provides 2023 Outlook
From Merus N.V.
Via GlobeNewswire
Merus Earnings Perspective: Return On Capital Employed
 
Via Benzinga
5 Analysts Have This to Say About Merus
 
Via Benzinga
What 4 Analyst Ratings Have To Say About Merus
Within the last quarter, Merus (NASDAQ:MRUS) has observed the following analyst ratings: 
Via Benzinga
Merus Provides 2023 Outlook
From Merus N.V.
Via GlobeNewswire
Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Third Quarter and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
From Merus N.V.
Via GlobeNewswire
4 Analysts Have This to Say About Merus
Within the last quarter, Merus (NASDAQ:MRUS) has observed the following analyst ratings: 
Via Benzinga
Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus
Incyte Corporation (NASDAQ: INCY) is  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
 
Via Benzinga
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry. 
Via Benzinga
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60. 
Via Benzinga
Albemarle To Rally Around 8%? Here Are 5 Other Price Target Changes For Thursday
Berenberg raised Albemarle Corporation (NYSE: ALB) price target from $260 to $270. Berenberg analyst Andres Castanos Mollor downgraded the stock from Buy to Hold. Albemarle shares fell 7.9% to close at... 
Via Benzinga
Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday
Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the... 
Via Benzinga
Analyst Casts Doubts On Merus' Lung Candidate Safety Profile
Earlier today, Merus N.V. (NASDAQ: MRUS) announced the publication of the abstract highlighting interim data from the ongoing phase 1/2 trial of the bispecific antibody MCLA-129 in advanced non-small... 
Via Benzinga
Why Seagate Shares Are Trading Lower By More Than 7%? Here Are 49 Stocks Moving In Wednesday's Mid-Day Session
Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares surged 59.3% to $2.7417 after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the 29th Annual Prostate... 
Via Benzinga
Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
From Merus N.V.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022
Upgrades 
Via Benzinga
Merus Stock Joins Rank Of Stocks With RS Ratings Over 90
On Thursday, Netherlands-based Merus stock had its Relative Strength (RS) Rating upgraded to 94 from 78 a day earlier. 
Via Investor's Business Daily
Needham Says Merus' ASCO Update On Zeno 'Positive'
Needham writes that Merus NV (NASDAQ: MRUS) has enough data to initiate an FDA marketing application filing in mid-2022 after presenting Zenocutuzumab (Zeno) data in NRG1-fusion (NRG1+) Cancer. 
Via Benzinga
7 Top-Rated Biotech Stocks to Buy for Q2
In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill. 
Via InvestorPlace
70 Biggest Movers From Friday
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,... 
Via Benzinga
Promising Developments in Breast Cancer Treatments Ahead in 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against... 
Via FinancialNewsMedia
Merus Shares Updated Data From Zeno Triplet Combo Data In Breast Cancer Settings
Merus NV (NASDAQ: MRUS) has presented updated data on zenocutuzumab (Zeno) combined with trastuzumab and vinorelbine in HER2 positive/amplified (HER2+) metastatic... 
Via Benzinga
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To... 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.